Publications by authors named "V Bonthapally"
Article Synopsis
- This analysis examined the effects of zuranolone, a treatment for major depressive disorder and postpartum depression, on health-related quality of life, using data from four clinical trials.
- Results indicated that patients taking zuranolone showed significant improvements in various health domains compared to those on placebo, both at 15 days and 42 days after treatment.
- Zuranolone responders demonstrated consistent benefits across all health aspects measured, with sustained improvements even after the treatment ended.
Article Synopsis
- Zuranolone, a treatment for postpartum depression (PPD), showed significant improvements in both anxiety and insomnia symptoms in women participating in a clinical study compared to a placebo.* -
- The study involved a double-blind, randomized trial with women aged 18-45 who had PPD, following treatment with either zuranolone or a placebo over a 14-day period.* -
- Results indicated higher rates of concurrent remission in depressive and anxiety symptoms with zuranolone, as well as positive effects on insomnia and overall functional health.*
Article Synopsis
- Major depressive disorder (MDD) significantly impacts health-related quality of life (HRQoL), and this study examined how the neuroactive steroid zuranolone affects HRQoL using the Short Form-36v2 Health Survey (SF-36v2).
- Adult patients with MDD were randomly assigned to receive either zuranolone or a placebo for two weeks, with HRQoL assessed across various domains at Day 15 showing substantial improvements for those treated with zuranolone, particularly in areas like Mental Health and Vitality.
- The results suggest that zuranolone leads to rapid and meaningful HRQoL enhancements compared to placebo, although the small sample size may limit generalizability and other factors could influence HRQoL
Objective: To evaluate the health-related quality of life (HRQoL) burden associated with postpartum depression (PPD), determine the extent to which clinical response impacts HRQoL, and estimate the impact of PPD and clinical response on healthcare resource utilization (HRU) and productivity.
Methods: Patient data ( = 127) from two multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trials evaluating the safety and efficacy of brexanolone injection in adults with PPD were employed for these posthoc analyses. HRQoL and health utility was assessed with the SF-36-v2 Health Survey (SF-36v2) acute version.